[1]李思文,张 燕.不同紫杉醇剂型联合卡铂治疗卵巢癌的疗效研究[J].医学信息,2019,(07):150-152.[doi:10.3969/j.issn.1006-1959.2019.07.046]
 LI Si-wen,ZHANG Yan.Therapeutic Effect of Different Paclitaxel Dosage Forms Combined With Carboplatin On Ovarian Cancer[J].Medical Information,2019,(07):150-152.[doi:10.3969/j.issn.1006-1959.2019.07.046]
点击复制

不同紫杉醇剂型联合卡铂治疗卵巢癌的疗效研究()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2019年07期
页码:
150-152
栏目:
药物与临床
出版日期:
2019-04-01

文章信息/Info

Title:
Therapeutic Effect of Different Paclitaxel Dosage Forms Combined With Carboplatin On Ovarian Cancer
文章编号:
1006-1959(2019)07-0150-03
作者:
李思文张 燕
(佳木斯大学附属第一医院妇产科,黑龙江 佳木斯 154002)
Author(s):
LI Si-wenZHANG Yan
(Department of Obstetrics and Gynecology,the First Affiliated Hospital of Jiamusi University, Jiamusi 154002,Heilongjiang,China)
关键词:
紫杉醇卡铂卵巢癌安全性近期疗效远期疗效医疗费用
Keywords:
PaclitaxelCarboplatinOvarian cancerSafetyShort-term efficacyLong-term efficacy Medical expenses
分类号:
R737.31
DOI:
10.3969/j.issn.1006-1959.2019.07.046
文献标志码:
A
摘要:
目的 观察卵巢癌(OC)患者中应用不同紫杉醇剂型联合卡铂的临床疗效。方法 收集我院2014年10月~2016年10月收治的70例OC患者的临床资料,随机分为甲组(38例)和乙组(32例),甲组患者采用注射用紫杉醇脂质体+卡铂治疗,乙组患者采用紫杉醇注射液+卡铂治疗,比较两组近期疗效、远期疗效、副作用、医疗费用。结果 甲组、乙组治疗总有效率分别为68.42%、65.63%,疾病控制率分别为81.58%、78.13%,差异均无统计学意义(P>0.05);甲组无进展生存期大于乙组[(15.79±3.02)个月 vs (13.42±2.13)个月],差异有统计学意义(P<0.05);两组总生存期比较,差异无统计学意义(P>0.05);甲组副作用发生率为10.53%,低于乙组的31.25%,差异有统计学意义(P<0.05);甲组医疗费用高于乙组,差异有统计学意义(P<0.05)。结论 OC治疗中紫杉醇脂质体联合卡铂与紫杉醇注射液联合卡铂近期疗效相当,前者可延长患者无进展生存期,且安全性更高,但医疗费用较高。
Abstract:
Objective To observe the clinical efficacy of different paclitaxel dosage forms combined with carboplatin in patients with ovarian cancer (OC). Methods The clinical data of 70 patients with OC admitted to our hospital from October 2014 to October 2016 were randomly divided into group A (38 cases) and group B (32 cases). Group A patients received paclitaxel liposome for injection. + Carboplatin treatment, group B patients were treated with paclitaxel injection + carboplatin, comparing the short-term efficacy, long-term efficacy, side effects, medical expenses of the two groups. ResultsThe total effective rate of treatment in group A and group B was 68.42% and 65.63%, respectively. The disease control rate was 81.58% and 78.13%, respectively,the difference was not statistically significant (P>0.05). The progression-free survival of group A was greater than that of group B[(15.79±3.02) months vs (13.42±2.13) months], the difference was statistically significant (P<0.05); there was no significant difference in the overall survival between the two groups (P>0.05); side effects of group A the incidence was 10.53%, which was lower than that of group B,the difference was statistically significant (P<0.05). The medical expenses of group A were higher than those of group B,the difference was statistically significant (P<0.05). Conclusion In the OC treatment, paclitaxel liposome combined with carboplatin and paclitaxel injection combined with carboplatin has the short-term effect. The former can prolong the progression-free survival of patients, and the safety is higher, but the medical expenses are higher.

参考文献/References:


[1]边策,綦小蓉,姚奎,等.新辅助化疗对晚期卵巢癌治疗应用价值的评估及多因素分析[J].实用妇产科杂志,2016,32(4):266-271.
[2]曾龙佳,卢芳芳,易素祎,等.晚期卵巢癌的新辅助化疗应用[J].中国妇幼保健,2016,31(14):2975-2978.
[3]阮冠宇,孙蓬明,林小梅.贝伐单抗联合化疗治疗卵巢癌有效性及安全性分析[J].中国妇产科临床杂志,2016,17(4):323-327.
[4]卢淮武,谢玲玲,林仲秋.《2016NCCN卵巢癌临床实践指南(第1版)》解读[J].中国实用妇科与产科杂志,2016,32(8):761-768.
[5]孙建衡.妇科恶性肿瘤放射治疗学[M].北京.协和医科大学出版社,2002:45-47.
[6]宋倪媛,陈徐,李霞,等.紫杉醇联合洛铂治疗晚期卵巢癌的效果及其对ERCC1、β-catenin、β-tubulin Ⅲ表达的影响[J].中国医药导报,2016,13(6):115-118.
[7]唐慕菲,朱余兵,李杨,等.紫杉醇脂质体与紫杉醇分别联合卡铂治疗卵巢癌疗效的Meta分析[J].中国药师,2018,21(4):52-54.
[8]Fernández A,Salgado M,García A,et al.Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study[J].BMC Cancer,2018,18(1):1185.
[9]梁楠楠,林琳,郗轶楠.紫杉醇与卡铂联合参麦注射液对中晚期卵巢癌患者外周血T细胞亚群及血清标志物变化的影响[J].中国肿瘤临床与康复,2018,25(3):11-13.
[10]李桂梅,刘冬梅,平伟,等.紫杉醇脂质体联合卡铂与紫杉醇联合卡铂治疗卵巢癌的疗效比较[J].中国肿瘤临床与康复,2016,23(5):563-565.
[11]侯文杰,徐建英,池迟,等.脂质体紫杉醇联合卡铂与紫杉醇联合卡铂治疗上皮性卵巢癌的疗效和安全性比较[J].肿瘤防治研究,2018,45(6):82-84.
[12]陈璐,周黎,李伊莎.卡铂联合紫杉醇对老年晚期卵巢癌患者的临床疗效及血清HE4、CA125水平的影响[J].世界临床药物,2017,38(4):252-256.
[13]张富斌,崔李宁,徐科君.紫杉醇脂质体与传统紫杉醇联合卡铂治疗卵巢癌的疗效及不良反应的对比分析[J].中华全科医学,2017,15(5):808-810.

相似文献/References:

[1]彭玉龙,张 露,陈荣辉,等.吉西他滨与培美曲塞联合卡铂治疗晚期肺腺癌的临床观察[J].医学信息,2018,(11):124.[doi:10.3969/j.issn.1006-1959.2018.11.039]
 PENG Yu-long,ZHANG Lu,CHEN Rong-hui,et al.Clinical Observation of Gemcitabine and Pemetrexed Combined with Carboplatin in Treatment of Advanced Lung Adenocarcinoma[J].Medical Information,2018,(07):124.[doi:10.3969/j.issn.1006-1959.2018.11.039]

更新日期/Last Update: 2019-04-01